A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
